儿童放疗诱发性乳头状与滤泡状甲状腺癌中基因融合和拷贝数改变的患病率高
研究对比了37例患儿共41例分化型甲状腺癌(放疗后11例、原发30例)的分子特征,采用靶向二代测序和/或BRAF免疫组化检测。放疗后乳头状癌基因融合占86%(6/7),原发乳头状癌占56%(14/25);放疗后滤泡状癌拷贝数改变占75%(3/4),原发滤泡状癌占40%(2/5)。
要点
- 放疗后乳头状甲状腺癌基因融合占86%(6/7),原发乳头状癌占56%(14/25)。
- 放疗后乳头状癌单核苷酸变异占14%(1/7),原发乳头状癌占44%(11/25)。
- 放疗后滤泡状癌拷贝数改变占75%(3/4),原发滤泡状癌占40%(2/5)。
核心结论
- 儿童放疗诱发性甲状腺癌的分子特征似乎与原发(散发和综合征性)病例不同,放疗后乳头状癌基因融合患病率高(类似切尔诺贝利核事故后发生的乳头状癌),放疗后滤泡状癌拷贝数改变患病率高。
- 更好地理解这些癌症的分子机制可能带来更准确的诊断、预后和治疗,因为部分基因组改变具有潜在靶向性。
研究设计与样本
- 研究纳入2010年1月1日至2019年12月31日在Phoenix Children's Hospital就诊的37例患者共41例分化型甲状腺癌(放疗后11例,原发30例)。
- 采用靶向二代测序和/或BRAF免疫组化进行评估。
主要发现
- 放疗后乳头状癌基因融合占86%(6/7),原发乳头状癌占56%(14/25)。
- 放疗后乳头状癌单核苷酸变异占14%(1/7,为DICER1基因点突变),原发乳头状癌占44%(11/25,均为BRAFV600E突变)。
- 在1例放疗后乳头状癌患儿中发现了极罕见的ROS1融合。
- 放疗后滤泡状癌拷贝数改变占75%(3/4),原发滤泡状癌占40%(2/5)。
- 放疗后滤泡状癌单核苷酸变异占0%(0/4),原发滤泡状癌占100%(5/5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Childhood cancer survivors and bone marrow transplant recipients treated with radiation therapy (RT) are at increased risk for subsequent thyroid cancer. However, the genetic landscape of pediatric thyroid cancer, both primary and RT-induced, remains poorly defined, as pediatric papillary thyroid carcinoma (PTC) has been understudied compared with adults and data on pediatric follicular thyroid carcinoma (FTC) are virtually nonexistent. The objective of this study was to characterize and compare the molecular profiles of pediatric RT-induced PTC and FTC cases with primary pediatric thyroid cancers. Methods: A total of 41 differentiated thyroid carcinomas (11 RT cases and 30 primary cases) from 37 patients seen at Phoenix Children's Hospital between January 1, 2010 and December 31, 2019 were evaluated by targeted next-generation sequencing and/or BRAF immunohistochemistry. Results: Eighty-six percent (6/7) of RT-PTC harbored a gene fusion (GF) compared with 56% (14/25) of primary PTC; 14% (1/7) of RT-PTC had a single-nucleotide variant (SNV; specifically, a point mutation in the DICER1 gene) compared with 44% (11/25) of primary PTC (all of the latter had the BRAFV600E mutation). An exceedingly rare ROS1 fusion was identified in a child with RT-PTC. With respect to FTC, copy number alterations (CNAs) were seen in 75% (3/4) of RT cases compared with 40% (2/5) of primary cases. None of the RT-FTC had SNVs compared with 100% (5/5) of primary FTC. Conclusions: In children, the molecular profile of subsequent RT-induced thyroid cancers appears to differ from primary (sporadic and syndromic) cases, with a high prevalence of GFs in RT-PTC (similar to PTC occurring after the Chernobyl nuclear reactor accident) and CNAs in RT-FTC. A better understanding of the molecular mechanisms underlying these cancers may lead to more accurate diagnosis, prognosis, and treatment, as some of the genomic alterations are potentially targetable.
引用
- Hess JR, Newbern DK, Beebe KL, et al. High Prevalence of Gene Fusions and Copy Number Alterations in Pediatric Radiation Therapy-Induced Papillary and Follicular Thyroid Carcinomas. Thyroid. 2022. PMID: 34915766. doi:10.1089/thy.2021.0217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。